These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 26181552

  • 1. Semi-Quantitative Calculations of Primary Tumor Metabolic Activity Using F-18 FDG PET/CT as a Predictor of Survival in 92 Patients With High-Grade Bone or Soft Tissue Sarcoma.
    Andersen KF, Fuglo HM, Rasmussen SH, Petersen MM, Loft A.
    Medicine (Baltimore); 2015 Jul; 94(28):e1142. PubMed ID: 26181552
    [Abstract] [Full Text] [Related]

  • 2. Volume-Based F-18 FDG PET/CT Imaging Markers Provide Supplemental Prognostic Information to Histologic Grading in Patients With High-Grade Bone or Soft Tissue Sarcoma.
    Andersen KF, Fuglo HM, Rasmussen SH, Petersen MM, Loft A.
    Medicine (Baltimore); 2015 Dec; 94(51):e2319. PubMed ID: 26705220
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of (18)F-FDG PET at diagnosis in patients with soft tissue sarcoma and bone sarcoma; systematic review and meta-analysis.
    Kubo T, Furuta T, Johan MP, Ochi M.
    Eur J Cancer; 2016 May; 58():104-11. PubMed ID: 26990930
    [Abstract] [Full Text] [Related]

  • 4. The diagnostic and prognostic value of ¹⁸F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients.
    Fuglø HM, Jørgensen SM, Loft A, Hovgaard D, Petersen MM.
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1416-24. PubMed ID: 22699526
    [Abstract] [Full Text] [Related]

  • 5. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing 18F-FDG PET/CT-derived parameters.
    Chen B, Feng H, Xie J, Li C, Zhang Y, Wang S.
    BMC Med Imaging; 2020 Jul 25; 20(1):85. PubMed ID: 32711449
    [Abstract] [Full Text] [Related]

  • 6. Necrosis on FDG PET/CT correlates with prognosis and mortality in sarcomas.
    Rakheja R, Makis W, Tulbah R, Skamene S, Holcroft C, Nahal A, Turcotte R, Hickeson M.
    AJR Am J Roentgenol; 2013 Jul 25; 201(1):170-7. PubMed ID: 23789672
    [Abstract] [Full Text] [Related]

  • 7. Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas.
    Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A, Willeke F, Cardona S, Mechtersheimer G, Lehnert T, Strauss LG, Herfarth C, Büchler MW.
    Ann Surg; 2005 Feb 25; 241(2):286-94. PubMed ID: 15650639
    [Abstract] [Full Text] [Related]

  • 8. Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome.
    Eary JF, Conrad EU, O'Sullivan J, Hawkins DS, Schuetze SM, O'Sullivan F.
    J Bone Joint Surg Am; 2014 Jan 15; 96(2):152-8. PubMed ID: 24430415
    [Abstract] [Full Text] [Related]

  • 9. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET.
    Benz MR, Dry SM, Eilber FC, Allen-Auerbach MS, Tap WD, Elashoff D, Phelps ME, Czernin J.
    J Nucl Med; 2010 Aug 15; 51(8):1174-81. PubMed ID: 20660389
    [Abstract] [Full Text] [Related]

  • 10. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
    Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU, Eary JF.
    Cancer; 2005 Jan 15; 103(2):339-48. PubMed ID: 15578712
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
    Iagaru A, Masamed R, Chawla SP, Menendez LR, Fedenko A, Conti PS.
    Clin Nucl Med; 2008 Jan 15; 33(1):8-13. PubMed ID: 18097248
    [Abstract] [Full Text] [Related]

  • 15. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
    Bastiaannet E, Groen H, Jager PL, Cobben DC, van der Graaf WT, Vaalburg W, Hoekstra HJ.
    Cancer Treat Rev; 2004 Feb 15; 30(1):83-101. PubMed ID: 14766127
    [Abstract] [Full Text] [Related]

  • 16. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis.
    Eary JF, O'Sullivan F, Powitan Y, Chandhury KR, Vernon C, Bruckner JD, Conrad EU.
    Eur J Nucl Med Mol Imaging; 2002 Sep 15; 29(9):1149-54. PubMed ID: 12192559
    [Abstract] [Full Text] [Related]

  • 17. Prognostic value of 18F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis.
    Chen L, Wu X, Ma X, Guo L, Zhu C, Li Q.
    Medicine (Baltimore); 2017 Feb 15; 96(6):e5913. PubMed ID: 28178131
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma.
    Hwang JP, Lim I, Byun BH, Kim BI, Choi CW, Lim SM.
    Nucl Med Commun; 2016 Dec 15; 37(12):1267-1272. PubMed ID: 27482643
    [Abstract] [Full Text] [Related]

  • 19. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
    Bahri H, Laurence L, Edeline J, Leghzali H, Devillers A, Raoul JL, Cuggia M, Mesbah H, Clement B, Boucher E, Garin E.
    J Nucl Med; 2014 Nov 15; 55(11):1786-90. PubMed ID: 25286923
    [Abstract] [Full Text] [Related]

  • 20. 18F-FDG PET/CT in Diagnostic and Prognostic Evaluation of Patients With Suspected Recurrence of Chondrosarcoma.
    Vadi SK, Mittal BR, Gorla AKR, Sood A, Basher RK, Sood A, Kakkar N, Sen RK.
    Clin Nucl Med; 2018 Feb 15; 43(2):87-93. PubMed ID: 29261626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.